Search for: "Lisa Ouellette" Results 121 - 140 of 155
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
27 Mar 2017, 4:18 am by Edith Roberts
At Written Description, Lisa Ouellette offers some “thoughts on the policy tradeoffs” at play in Impression Products, Inc. v. [read post]
6 Feb 2015, 6:00 am by Bridget Crawford
Lisa Larrimore Ouellette (Stanford) (@PatentScholar) has created a Twitter list that makes it easier to follow all of the professors listed in the census. [read post]
6 Jan 2015, 6:46 pm by Bridget Crawford
Thomas Anthony Niedwiecki LawProfAnt John Marshall (Chicago) Sean Nolon snolon Vermont Tracy Norton millennialprof Touro Tracy Norton profnorton Touro Beth Simone Noveck bethnoveck NYLS Rory O'Connell rjjoconnell Queens University Belfast Shuyi Oei ShuyiOei Tulane Paul Ohm paulohm Colorado David Opderbeck dopderbeck Seton Hall Lisa Ouellette PatentScholar Stanford Kevin Outterson koutterson Boston University Jessica Owley JessicaOwley Buffalo Frank Pasquale FrankPasquale Seton… [read post]
9 Mar 2018, 12:54 pm by Camilla Alexandra Hrdy
To give one example, in their recent article, Bayh-Dole Without Borders, Lisa Larrimore Ouellette and Daniel Hemel observe that an under-appreciated feature of making federal funding for research work as an economic policy is ensuring that U.S. companies are able to protect the results of that federally-funded research abroad. [read post]
9 Mar 2018, 12:54 pm by Camilla Alexandra Hrdy
To give one example, in their recent article, Bayh-Dole Without Borders, Lisa Larrimore Ouellette and Daniel Hemel observe that an under-appreciated feature of making federal funding for research work as an economic policy is ensuring that U.S. companies are able to protect the results of that federally-funded research abroad. [read post]
15 Apr 2020, 8:14 am by Lisa Larrimore Ouellette
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob SherkowIt’s now clear that expansive, population-wide testing is part-and-parcel of every successful COVID-19 containment strategy. [read post]
15 Apr 2020, 8:14 am by Lisa Larrimore Ouellette
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob SherkowIt’s now clear that expansive, population-wide testing is part-and-parcel of every successful COVID-19 containment strategy. [read post]
30 Mar 2020, 8:40 am by Lisa Larrimore Ouellette
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob SherkowOne of the dizzying stream of innovation and health law stories to emerge last week is Oracle’s partnership with the White House to study unproven pharmaceuticals for treating COVID-19. [read post]
30 Mar 2020, 8:40 am by Lisa Larrimore Ouellette
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob SherkowOne of the dizzying stream of innovation and health law stories to emerge last week is Oracle’s partnership with the White House to study unproven pharmaceuticals for treating COVID-19. [read post]
21 Apr 2020, 2:09 pm by Lisa Larrimore Ouellette
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob SherkowOur recent posts have highlighted shortages in three COVID-19-related knowledge goods: testing, drugs (such as those needed to put patients on ventilators), and clinical trial information about effective treatments. [read post]
21 Apr 2020, 2:09 pm by Lisa Larrimore Ouellette
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob SherkowOur recent posts have highlighted shortages in three COVID-19-related knowledge goods: testing, drugs (such as those needed to put patients on ventilators), and clinical trial information about effective treatments. [read post]
18 Jun 2020, 1:23 pm by Lisa Larrimore Ouellette
Sherkow, Lisa Larrimore Ouellette, Nicholson Price, and Rachel SachsIn the United States, one of the most important factors in receiving COVID-19 testing or treatment is access to insurance. [read post]
18 Jun 2020, 1:23 pm by Lisa Larrimore Ouellette
Sherkow, Lisa Larrimore Ouellette, Nicholson Price, and Rachel SachsIn the United States, one of the most important factors in receiving COVID-19 testing or treatment is access to insurance. [read post]
19 May 2020, 3:30 pm by Lisa Larrimore Ouellette
Sherkow, Lisa Larrimore Ouellette, Nicholson Price, and Rachel SachsLast week, we focused on incentives for developing clinical evidence supporting the use of remdesivir for COVID-19 and analyzed the FDA’s grant of an emergency use authorization (EUA) for the drug. [read post]
19 May 2020, 3:30 pm by Lisa Larrimore Ouellette
Sherkow, Lisa Larrimore Ouellette, Nicholson Price, and Rachel SachsLast week, we focused on incentives for developing clinical evidence supporting the use of remdesivir for COVID-19 and analyzed the FDA’s grant of an emergency use authorization (EUA) for the drug. [read post]
5 Mar 2018, 10:43 am by Camilla Alexandra Hrdy
 On its face, the report flawed for measuring intellectual property’s impact on employment for two reasons – one of which is fatal.The first flaw, which Lisa Ouellette and the authors of the report themselves have pointed out, is that its methodology does not measure, or even try to measure, the causal connection between the incentive effects of intellectual property, and the documented impact on jobs and wages. [read post]
5 Mar 2018, 10:43 am by Camilla Alexandra Hrdy
On its face, the report flawed for measuring intellectual property’s impact on employment for two reasons – one of which is fatal.The first flaw, which Lisa Ouellette and the authors of the report themselves have pointed out, is that its methodology does not measure, or even try to measure, the causal connection between the incentive effects of intellectual property, and the documented impact on jobs and wages.** In other words, it could be true that IP-intensive… [read post]